[go: up one dir, main page]

SI2820013T1 - Modulatorji jetrnega x receptorja za zdravljenje dermalnih bolezni, motenj in stanj - Google Patents

Modulatorji jetrnega x receptorja za zdravljenje dermalnih bolezni, motenj in stanj

Info

Publication number
SI2820013T1
SI2820013T1 SI201331198T SI201331198T SI2820013T1 SI 2820013 T1 SI2820013 T1 SI 2820013T1 SI 201331198 T SI201331198 T SI 201331198T SI 201331198 T SI201331198 T SI 201331198T SI 2820013 T1 SI2820013 T1 SI 2820013T1
Authority
SI
Slovenia
Prior art keywords
lxr
modulators
disorders
liver
receptor
Prior art date
Application number
SI201331198T
Other languages
English (en)
Inventor
Raju Mohan
Original Assignee
Ralexar Therapeutics, Inc,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ralexar Therapeutics, Inc, filed Critical Ralexar Therapeutics, Inc,
Publication of SI2820013T1 publication Critical patent/SI2820013T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/16—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
SI201331198T 2012-03-02 2013-02-28 Modulatorji jetrnega x receptorja za zdravljenje dermalnih bolezni, motenj in stanj SI2820013T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261606160P 2012-03-02 2012-03-02
EP13754329.4A EP2820013B9 (en) 2012-03-02 2013-02-28 Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions
PCT/US2013/028438 WO2013130892A1 (en) 2012-03-02 2013-02-28 Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions

Publications (1)

Publication Number Publication Date
SI2820013T1 true SI2820013T1 (sl) 2018-11-30

Family

ID=49083313

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201331198T SI2820013T1 (sl) 2012-03-02 2013-02-28 Modulatorji jetrnega x receptorja za zdravljenje dermalnih bolezni, motenj in stanj

Country Status (26)

Country Link
US (5) US8987318B2 (sl)
EP (2) EP3441390A1 (sl)
JP (2) JP6378630B2 (sl)
KR (1) KR102112879B1 (sl)
CN (1) CN104284893B (sl)
AU (1) AU2013225840B2 (sl)
BR (1) BR112014021515A2 (sl)
CA (1) CA2866113C (sl)
CY (1) CY1120742T1 (sl)
DK (1) DK2820013T3 (sl)
ES (1) ES2691079T3 (sl)
HK (1) HK1206030A1 (sl)
HR (1) HRP20181623T1 (sl)
HU (1) HUE040231T2 (sl)
IL (1) IL234413B (sl)
LT (1) LT2820013T (sl)
MX (1) MX361349B (sl)
NZ (1) NZ629636A (sl)
PL (1) PL2820013T3 (sl)
PT (1) PT2820013T (sl)
RS (1) RS57863B9 (sl)
SG (2) SG11201405378VA (sl)
SI (1) SI2820013T1 (sl)
SM (1) SMT201800630T1 (sl)
TR (1) TR201815013T4 (sl)
WO (1) WO2013130892A1 (sl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2820013T1 (sl) 2012-03-02 2018-11-30 Ralexar Therapeutics, Inc, Modulatorji jetrnega x receptorja za zdravljenje dermalnih bolezni, motenj in stanj
US9751869B2 (en) * 2013-03-15 2017-09-05 Bristol-Myers Squibb Company LXR modulators
CN104151300B (zh) * 2013-05-15 2018-07-13 中国医学科学院医药生物技术研究所 一组2,3-二取代的苯并喹唑啉类的肝x受体的激动剂及用途
WO2015035015A1 (en) 2013-09-04 2015-03-12 Alexar Therapeutics, Inc. Liver x receptor (lxr) modulators
CA2923178A1 (en) * 2013-09-04 2015-03-12 Alexar Therapeutics, Inc. Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions
CA2939120A1 (en) 2014-01-10 2015-07-16 Rgenix, Inc. Lxr agonists and uses thereof
WO2017115319A2 (en) 2015-12-30 2017-07-06 Consejo Nacional De Investigaciones Científicas Y Técnicas (Conicet) Use of brassinosteroid analogs for the treatment of dermal disorders by selectively modulating liver x receptors (lxr) and dermal disease treatment by brassinosteroid analogs acting as selective liver x receptor (lxr) modulators
CA3010883A1 (en) 2016-01-11 2017-07-20 The Rockefeller University Methods for the treatment of myeloid derived suppressor cells related disorders
CA3078981A1 (en) 2017-11-21 2019-05-31 Rgenix, Inc. Polymorphs and uses thereof
CN114126618A (zh) 2019-07-15 2022-03-01 诺华股份有限公司 用肝脏x受体激动剂治疗睑板腺功能障碍的方法
CA3161274A1 (en) 2019-12-13 2021-06-17 Stephen Wald Metal salts and uses thereof
WO2022249006A1 (en) * 2021-05-24 2022-12-01 Novartis Ag Use of 1,2,4-oxadiazole derivatives as liver x receptor agonists

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1199771A (en) * 1915-07-01 1916-10-03 Bates Valve Bag Co Wire-twisting machine.
ATE283253T1 (de) 2000-09-18 2004-12-15 Glaxo Group Ltd Substituierte aminopropoxyarylderivate als lxr agonisten
AUPR738301A0 (en) 2001-08-30 2001-09-20 Starpharma Limited Chemotherapeutic agents
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
EP1509495A1 (en) 2002-05-24 2005-03-02 Pharmacia Corporation Anilino liver x-receptor modulators
MXPA04011690A (es) 2002-05-24 2005-03-31 Pharmacia Corp Moduladores de receptor x de higado de sulfona.
WO2004058717A1 (en) 2002-12-20 2004-07-15 X-Ceptor Therapeutics, Inc. Isoquinolinone derivatives and their use as therapeutic agents
JP2006193426A (ja) 2003-09-05 2006-07-27 Sankyo Co Ltd 置換された縮環ピリミジン−４（３ｈ）−オン化合物
WO2005113499A1 (ja) 2004-05-20 2005-12-01 Sankyo Company, Limited インドール化合物
TW200606133A (en) 2004-06-30 2006-02-16 Sankyo Co Substituted benzene compounds
CN101213194A (zh) 2004-08-03 2008-07-02 惠氏公司 可用于治疗心血管疾病的吲唑化合物
US20070060589A1 (en) * 2004-12-21 2007-03-15 Purandare Ashok V Inhibitors of protein arginine methyl transferases
WO2006109633A1 (ja) 2005-04-07 2006-10-19 Daiichi Sankyo Company, Limited 置換インドール化合物
US7213797B2 (en) 2005-05-20 2007-05-08 Garland Jerome Gaskins Deck board straightener
CN101248049B (zh) * 2005-06-27 2013-08-28 埃克塞利希斯专利有限责任公司 咪唑类lxr调节剂
MX2008000141A (es) 2005-06-27 2008-04-07 Exelixis Inc Moduladores de lxr basados en imidazol.
DK1940786T3 (da) 2005-09-16 2010-11-08 Arrow Therapeutics Ltd Biphenylderivater og deres anvendelse ved behandling af hepatitis C
WO2007034279A2 (en) 2005-09-19 2007-03-29 Pfizer Products Inc. C3a antagonists and pharmaceutical compositions thereof
CN101309915A (zh) 2005-11-14 2008-11-19 Irm责任有限公司 作为lxr调节剂的化合物和组合物
EP1849781A1 (en) 2006-04-28 2007-10-31 Laboratorios del Dr. Esteve S.A. Substituted 3-Amino-4-hydroxy pyrrolidines compounds, their preparation and use as medicaments
TW200825054A (en) 2006-10-18 2008-06-16 Wyeth Corp Quinoline compounds
EP2121621B1 (en) 2006-12-08 2014-05-07 Exelixis Patent Company LLC Lxr and fxr modulators
US8338437B2 (en) * 2007-02-28 2012-12-25 Methylgene Inc. Amines as small molecule inhibitors
JP2010527930A (ja) 2007-05-18 2010-08-19 ワイス・エルエルシー キナゾリン化合物
US20090069288A1 (en) * 2007-07-16 2009-03-12 Breinlinger Eric C Novel therapeutic compounds
CA2695088C (en) 2007-08-13 2013-03-12 F. Hoffmann-La Roche Ag Novel piperazine amide derivatives
CA2710461A1 (en) 2007-12-21 2009-07-09 Wyeth Llc Benzimidazole compounds
WO2009086123A1 (en) 2007-12-21 2009-07-09 Wyeth Imidazo [1,2-a] pyridine compounds
US20120015988A1 (en) * 2008-05-13 2012-01-19 Boehringer Ingelheim International Gmbh Sulfone Compounds Which Modulate The CB2 Receptor
US8063088B2 (en) 2008-06-11 2011-11-22 Hoffmann-La Roche Inc. Imidazolidine derivatives
CA2741537A1 (en) 2008-11-07 2010-05-14 Wyeth Llc Quinoxaline-based lxr modulators
EP2367801A1 (en) 2008-11-19 2011-09-28 Wyeth LLC Polar quinazolines as liver x receptors ( lxrs ) modulators
US8759337B2 (en) 2008-12-22 2014-06-24 Merck Sharp & Dohme Corp. Gamma secretase modulators
WO2010096170A2 (en) * 2009-02-19 2010-08-26 President And Fellows Of Harvard College Inhibition of trna synthetases and therapeutic applications thereof
WO2010096777A1 (en) 2009-02-23 2010-08-26 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
PT2435410T (pt) 2009-05-28 2017-05-03 Bristol Myers Squibb Co Resumo
ES2620177T3 (es) 2009-10-15 2017-06-27 Guerbet Agentes de formación de imágenes y su uso para el diagnóstico in vivo de enfermedades neurodegenerativas, particularmente la enfermedad de Alzheimer y enfermedades derivadas
GB0919757D0 (en) 2009-11-12 2009-12-30 Johnson Matthey Plc Polymorphs of bromfenac sodium and methods for preparing bromfenac sodium polymorphs
US8906943B2 (en) 2010-08-05 2014-12-09 John R. Cashman Synthetic compounds and methods to decrease nicotine self-administration
WO2012020820A1 (ja) * 2010-08-11 2012-02-16 大正製薬株式会社 ヘテロアリール－ピラゾール誘導体
US9079891B2 (en) * 2010-08-27 2015-07-14 Calcimedica, Inc. Compounds that modulate intracellular calcium
AR088728A1 (es) 2011-03-25 2014-07-02 Bristol Myers Squibb Co Moduladores de lxr como prodroga de imidazol
SI2820013T1 (sl) 2012-03-02 2018-11-30 Ralexar Therapeutics, Inc, Modulatorji jetrnega x receptorja za zdravljenje dermalnih bolezni, motenj in stanj
CN104780976B (zh) 2012-08-13 2019-01-01 洛克菲勒大学 治疗和诊断黑素瘤
CA2923178A1 (en) 2013-09-04 2015-03-12 Alexar Therapeutics, Inc. Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions
WO2015035015A1 (en) 2013-09-04 2015-03-12 Alexar Therapeutics, Inc. Liver x receptor (lxr) modulators

Also Published As

Publication number Publication date
HK1206030A1 (en) 2015-12-31
NZ629636A (en) 2017-02-24
CY1120742T1 (el) 2019-12-11
ES2691079T9 (es) 2019-02-08
ES2691079T3 (es) 2018-11-23
JP6800922B2 (ja) 2020-12-16
TR201815013T4 (tr) 2018-11-21
SG10201607345YA (en) 2016-11-29
PL2820013T3 (pl) 2019-01-31
KR102112879B1 (ko) 2020-05-19
MX2014010537A (es) 2015-03-09
HRP20181623T1 (hr) 2018-12-14
JP6378630B2 (ja) 2018-08-22
US20180370959A1 (en) 2018-12-27
JP2015512883A (ja) 2015-04-30
US8987318B2 (en) 2015-03-24
US20210101895A1 (en) 2021-04-08
EP2820013A1 (en) 2015-01-07
EP2820013B1 (en) 2018-07-11
KR20140146089A (ko) 2014-12-24
WO2013130892A1 (en) 2013-09-06
CN104284893B (zh) 2017-04-19
IL234413B (en) 2018-05-31
AU2013225840A1 (en) 2014-09-18
CN104284893A (zh) 2015-01-14
US20150045399A1 (en) 2015-02-12
HUE040231T2 (hu) 2019-02-28
CA2866113A1 (en) 2013-09-06
SMT201800630T1 (it) 2019-01-11
PT2820013T (pt) 2018-10-25
RS57863B1 (sr) 2018-12-31
LT2820013T (lt) 2018-10-25
EP2820013B9 (en) 2019-01-09
EP2820013A4 (en) 2015-11-11
US20150152094A1 (en) 2015-06-04
RS57863B9 (sr) 2019-10-31
MX361349B (es) 2018-12-04
SG11201405378VA (en) 2014-09-26
BR112014021515A2 (pt) 2018-03-13
DK2820013T3 (en) 2018-10-29
US20170334897A1 (en) 2017-11-23
US9637481B2 (en) 2017-05-02
AU2013225840B2 (en) 2017-11-23
CA2866113C (en) 2020-05-12
JP2018184467A (ja) 2018-11-22
EP3441390A1 (en) 2019-02-13

Similar Documents

Publication Publication Date Title
HRP20181623T1 (hr) Modulatori x receptora jetre (lxr) za liječenje bolesti, poremećaja i stanja kože
IL269852B (en) Combined treatments and uses for the treatment of demyelination disorders
HK1210968A1 (en) Compositions and treatment for eye diseases and disorders
IL225239A0 (en) Compounds for the treatment of acne and related diseases
HK1198909A1 (en) Compositions and methods for the treatment of hepatic diseases and disorders
IL232334A0 (en) Modulators of the G protein-coupled mas receptor and the treatment of related disorders
IL235058A0 (en) Pharmaceutical combinations for the treatment of metabolic disorders
HK1201826A1 (en) Benzamide derivatives as modulators of the follicle stimulating hormone
HK1219224A1 (zh) 角結膜病症的治療劑
PL392436A1 (pl) Pochodne arylosulfonamidów do leczenia chorób odśrodkowego układu nerwowego
HK1216721A1 (zh) 治療肝臟疾病或病狀的用途和方法
EP2723325A4 (en) NEW FORMULATIONS AND METHODS FOR TREATING DERMATOLOGICAL DISORDERS OR DISEASES
EP2900239A4 (en) DIHYDRO-6-AZAPHENAL DERIVATIVE FOR THE TREATMENT OF CNS DISEASES, ONCOLOGICAL DISEASES AND RELATED DISEASES
PL395469A1 (pl) Pochodne indoloamin do leczenia chorób osrodkowego ukladu nerwowego
IL245511A0 (en) Compositions and methods for treating viral diseases with 4pde modulators
AU2012900788A0 (en) Combination treatment for rheumatic disorders
AU2012904982A0 (en) Device for treating respiratory disorders